iSpecimen Inc. (ISPC)
NASDAQ: ISPC · Real-Time Price · USD
0.247
-0.008 (-3.25%)
Mar 5, 2026, 4:00 PM EST - Market closed

Company Description

iSpecimen Inc. operates marketplace that provides biospecimens to life science researchers worldwide.

The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them.

Its marketplace offers human biospecimens, including Biofluids, such as whole blood, plasma, serum, urine, saliva, sputum, nasopharyngeal material, and cerebral spinal fluid; Solid tissue comprising fresh, fixed, and cryopreserved tissue, as well as formalin-fixed paraffin embedded blocks, slides, and curls; and Hematopoietic stem and immune cells, including bone marrow, cord blood, whole blood, or sub-components of these tissues, such as peripheral blood mononuclear cells and other isolated cell types.

The company serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions.

iSpecimen Inc. was incorporated in 2009 and is headquartered in Woburn, Massachusetts.

iSpecimen Inc.
iSpecimen logo
Country United States
Founded 2009
IPO Date Jun 17, 2021
Industry Diagnostics & Research
Sector Healthcare
Employees 24
CEO Katharyn Field

Contact Details

Address:
8 Cabot Road
Woburn, Massachusetts 02420
United States
Phone 781 301 6700
Website ispecimen.com

Stock Details

Ticker Symbol ISPC
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
IPO Price $8.00
CIK Code 0001558569
CUSIP Number 45032V108
ISIN Number US45032V2079
Employer ID 27-0480143
SIC Code 8731

Key Executives

Name Position
Katharyn Field Chief Executive Officer, President, Secretary and Treasurer
Yuying Liang Chief Financial Officer

Latest SEC Filings

Date Type Title
Mar 3, 2026 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Feb 23, 2026 8-K Current Report
Feb 18, 2026 8-K Current Report
Feb 6, 2026 8-K Current Report
Feb 3, 2026 424B3 Prospectus
Jan 30, 2026 EFFECT Notice of Effectiveness
Jan 27, 2026 8-K Current Report
Jan 20, 2026 S-3 Registration statement under Securities Act of 1933
Jan 16, 2026 8-K/A [Amend] Current report
Jan 6, 2026 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material